Editas Medicine Inc
Company Profile
Business description
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
Contact
11 Hurley Street
CambridgeMA02141
USAT: +1 617 401-9000
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
226
Stocks News & Analysis
stocks
Unconventional wisdom: Are dividends the answers?
stocks
Netflix: A business that’s nearly flawless
stocks
Trump’s US dollar assault is fuelling CBA’s rise
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,937.70 | 41.70 | -0.46% |
CAC 40 | 7,818.28 | 32.15 | -0.41% |
DAX 40 | 24,295.93 | 55.11 | 0.23% |
Dow JONES (US) | 44,693.91 | 316.38 | -0.70% |
FTSE 100 | 9,138.37 | 76.88 | 0.85% |
HKSE | 25,406.55 | 260.63 | -1.02% |
NASDAQ | 21,057.96 | 37.94 | 0.18% |
Nikkei 225 | 41,570.24 | 256.10 | -0.61% |
NZX 50 Index | 12,875.15 | 70.02 | 0.55% |
S&P 500 | 6,363.35 | 4.44 | 0.07% |
S&P/ASX 200 | 8,669.40 | 40.00 | -0.46% |
SSE Composite Index | 3,591.41 | 14.32 | -0.40% |